- Home
- NIVF vs EVOK Comparison
NIVF vs EVOK Comparison
Compare NIVF & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- EVOK
- Stock Information
- Founded
- NIVF 2011
- EVOK 2007
- Country
- NIVF Hong Kong
- EVOK United States
- Employees
- NIVF N/A
- EVOK N/A
- Industry
- NIVF
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- EVOK Health Care
- Exchange
- NIVF NYSE
- EVOK Nasdaq
- Market Cap
- NIVF 3.9M
- EVOK 4.2M
- IPO Year
- NIVF N/A
- EVOK 2013
- Fundamental
- Price
- NIVF $0.71
- EVOK $2.45
- Analyst Decision
- NIVF
- EVOK
- Analyst Count
- NIVF 0
- EVOK 0
- Target Price
- NIVF N/A
- EVOK N/A
- AVG Volume (30 Days)
- NIVF 357.8K
- EVOK 27.3K
- Earning Date
- NIVF 01-01-0001
- EVOK 03-13-2025
- Dividend Yield
- NIVF N/A
- EVOK N/A
- EPS Growth
- NIVF N/A
- EVOK N/A
- EPS
- NIVF N/A
- EVOK N/A
- Revenue
- NIVF $5,679,218.00
- EVOK $10,249,415.00
- Revenue This Year
- NIVF N/A
- EVOK $99.03
- Revenue Next Year
- NIVF N/A
- EVOK $60.15
- P/E Ratio
- NIVF N/A
- EVOK N/A
- Revenue Growth
- NIVF N/A
- EVOK 97.84
- 52 Week Low
- NIVF $0.11
- EVOK $2.40
- 52 Week High
- NIVF $9.15
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- NIVF 54.67
- EVOK 26.36
- Support Level
- NIVF $0.56
- EVOK $2.51
- Resistance Level
- NIVF $0.77
- EVOK $2.81
- Average True Range (ATR)
- NIVF 0.15
- EVOK 0.29
- MACD
- NIVF -0.01
- EVOK -0.02
- Stochastic Oscillator
- NIVF 75.99
- EVOK 8.12
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.